

Discontinuation of Tetanus Toxoid Adsorbed Vaccine

May 2013


Dear Health Care Professional:

As a valued customer of Sanofi Pasteur, we want to alert you in advance that we will discontinue distribution of Tetanus Toxoid Adsorbed vaccine (NDC Number 49281-0820-10) in early 2014. The decision to discontinue Tetanus Toxoid Adsorbed vaccine, which is indicated for persons 7 years of age or older, was based on declining demand in the medical community.

Sanofi Pasteur offers several other tetanus toxoid-containing vaccines to help you follow the Advisory Committee on Immunization Practices (ACIP) recommendations. The company offers Adacel[®] (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) (NDC Numbers 49281-0400-10 and 49281-0400-15) and TENIVAC[®] (Tetanus and Diphtheria Toxoids Adsorbed) (NDC Numbers 49281-0215-10 and 49281-0215-15). To learn more about these products, please visit www.vaccineshoppe.com.

By notifying you in advance of this discontinuation, we hope to provide you with ample time to plan appropriately. If you have questions regarding the discontinuation of Tetanus Toxoid Adsorbed vaccine, please contact our customer account representatives at 1-800-VACCINE (1-800-822-2463).

Sincerely,



David Greenberg, MD
Vice President, Scientific and Medical Affairs and Chief Medical Officer
Sanofi Pasteur USA

MKT26367-2